Company

Legend Biotech’s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed/Refractory B-Cell Lymphoma with No Serious Safety Events

Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19/CD20...

Company Drug

Kelun-Biotech’s Novel B7-H3 ADC SKB500 Shows 42.7% Response Rate Across Multiple Solid Tumors in First-in-Human ASCO 2026 Presentation

Fineline Cube Jun 3, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) unveiled first-in-human clinical data for its investigational B7-H3-targeting...

Company Drug

Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment

Fineline Cube Jun 3, 2026

Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration...

Company Drug

AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial

Fineline Cube Jun 3, 2026

AstraZeneca plc (NYSE: AZN) announced updated results from the Phase III SERENA-6 clinical trial, demonstrating...

Company Drug

SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials

Fineline Cube Jun 3, 2026

Izalontamabbrengitecan (iza-bren), an EGFR and HER3-targeted antibody-drug conjugate (ADC) jointly developed by SystImmune (a subsidiary...

Company Drug

CSPC Pharmaceutical’s B7-H3 ADC SYS 6043 Shows 41.8% Response Rate in Phase I Solid Tumor Study

Fineline Cube Jun 3, 2026

CSPC Pharmaceutical Group Ltd. (HKG: 1093) presented Phase I clinical data for SYS 6043, a...

Company Deals

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Fineline Cube Jun 2, 2026

Rallybio Corporation (NASDAQ: RLYB) announced a definitive agreement to acquire Avenzo Therapeutics, Inc. through a...

Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

Fineline Cube Jun 2, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced a strategic commercial partnership with PrimeGenX Therapeutics Co.,...

Company Drug

Amgen’s Tarlatamab Receives EC Approval for Extensive-Stage SCLC with 40% Mortality Reduction in Phase III Trial

Fineline Cube Jun 2, 2026

Amgen Inc. (NASDAQ: AMGN) announced that the European Commission (EC) has granted marketing approval for...

Company Deals

Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion

Fineline Cube Jun 2, 2026

Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy...

Company Drug

Alphamab Oncology’s HER3×TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026

Fineline Cube Jun 2, 2026

Alphamab Oncology (HKG: 9966) presented groundbreaking Phase I clinical data at the 2026 American Society...

Company Drug

Sino Biopharmaceutical’s Saitanxin Shows 32.4% Response Rate in CDK4/6 Inhibitor-Resistant Breast Cancer at ASCO 2026

Fineline Cube Jun 2, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...

Company Deals

HemaCell Therapeutics Secures $44 Million Series B to Advance World’s First Megakaryocyte Injection for Platelet Regeneration

Fineline Cube Jun 2, 2026

Suzhou HemaCell Therapeutics (HemaCell), a pioneering cell therapy developer focused on platelet regeneration, announced the...

Company Drug

Haisco Pharmaceutical Secures FDA Approval for Cypsedo as First Chinese-Developed Intravenous Anesthetic in US Market

Fineline Cube Jun 2, 2026

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced it has received marketing approval from the...

Company Drug

Shionogi’s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA

Fineline Cube Jun 2, 2026

Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

BMS’ Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment

Fineline Cube Jun 2, 2026

Bristol-Myers Squibb Co. (BMS, NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Livzon Pharmaceutical Secures NMPA Approval for LZM012/XKH004, China’s First IL-17A/F Dual Inhibitor for Ankylosing Spondylitis

Fineline Cube Jun 2, 2026

Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China’s National...

Company Drug

Changchun High & New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3Kα Inhibitor for PIK3CA-Mutant Solid Tumors

Fineline Cube Jun 2, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical...

Company Drug

Changchun High & New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis

Fineline Cube Jun 2, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational...

Company Drug

Legend Biotech Unveils First-in-Human Data for DLL3-Targeted CAR-T Therapy LB2102 in Relapsed Small Cell Lung Cancer at ASCO 2026

Fineline Cube Jun 2, 2026

Legend Biotech Corporation (NASDAQ: LEGN) presented groundbreaking first-in-human (FIH) clinical data at the 2026 American...

Company

Legend Biotech’s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed/Refractory B-Cell Lymphoma with No Serious Safety Events

Kelun-Biotech’s Novel B7-H3 ADC SKB500 Shows 42.7% Response Rate Across Multiple Solid Tumors in First-in-Human ASCO 2026 Presentation

Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment

AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial

SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials

CSPC Pharmaceutical’s B7-H3 ADC SYS 6043 Shows 41.8% Response Rate in Phase I Solid Tumor Study

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

Amgen’s Tarlatamab Receives EC Approval for Extensive-Stage SCLC with 40% Mortality Reduction in Phase III Trial

Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion

Alphamab Oncology’s HER3×TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026

Sino Biopharmaceutical’s Saitanxin Shows 32.4% Response Rate in CDK4/6 Inhibitor-Resistant Breast Cancer at ASCO 2026

HemaCell Therapeutics Secures $44 Million Series B to Advance World’s First Megakaryocyte Injection for Platelet Regeneration

Haisco Pharmaceutical Secures FDA Approval for Cypsedo as First Chinese-Developed Intravenous Anesthetic in US Market

Shionogi’s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA

BMS’ Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment

Livzon Pharmaceutical Secures NMPA Approval for LZM012/XKH004, China’s First IL-17A/F Dual Inhibitor for Ankylosing Spondylitis

Changchun High & New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3Kα Inhibitor for PIK3CA-Mutant Solid Tumors

Changchun High & New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis

Legend Biotech Unveils First-in-Human Data for DLL3-Targeted CAR-T Therapy LB2102 in Relapsed Small Cell Lung Cancer at ASCO 2026

You Missed

NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy

Harbour BioMed’s TSLP Inhibitor HBM9378/WIN378 Doses First Patient in Phase II COPD Study with Windward Bio, Supporting Twice-Yearly Dosing Regimen

Haisco Pharmaceutical Files Nav1.8 Inhibitor HSK51155 with NMPA Following $700M+ AbbVie Licensing Deal for Novel Pain Therapeutic

Huadong Medicine’s Ellansé S Dermal Filler Receives NMPA Acceptance for Forehead Contouring Indication, Expanding China’s Premium Aesthetic Portfolio